Richard Brian Gaynor
Independent DirectorDr. Richard Brian Gaynor, M.D. served as Scientific Board Member at Cypherpunk Technologies Inc. (formerly known as Leap Therapeutics, Inc.) since 2021. Dr. Gaynor have served as an Independent Director at Zai Lab Limited since November 19, 2021. He serves as an Independent Director of Alkermes plc since September 2019. He has been President of BioNTech US Inc. since July 2020 and also serves as its Chief of R&D since July 2020. He served as Independent Director at Infinity Pharmaceuticals, Inc. since March 16, 2020 until March 2024. He had been President of Research and Development at BioNTech US Inc. (formerly known as Neon Therapeutics, Inc.). since November 07, 2016 until July 2020. He has experience in oncology-focused industrial drug development in addition to a distinguished career in academic medicine. He is board-certified in internal medicine and medical oncology and hematology. Dr. Gaynor served as Senior Vice President of Global Development & Medical Affairs for Oncology Business at Eli Lilly and Company since 2013 until 2016. He retired from Eli Lilly?s oncology division. He held related senior roles at Lilly Oncology, where he led preclinical and early clinical research, directed the biomarker and research group. Dr. Gaynor began his career in academia, spending on the faculty at UCLA School of Medicine followed on the faculty at UT Southwestern Medical School, including time serving as the Chief of hematology-oncology and Director of the Simmons Cancer Center. In 2002, Dr. Gaynor moved to Eli Lilly where he began his industry career overseeing both oncology drug discovery and early clinical development. Dr. Gaynor helped oversee a variety of collaborations, including with Bristol-Myers Squibb, Merck, AstraZeneca and GE. He is the Author of nearly 150 publications and participates on numerous boards, including several with the AACR, the MD Anderson Moon Shots advisory board, the Damon Runyon Cancer Research Foundation and Accelerating Cancer Cures. Dr. Gaynor holds an M.D. from the University of Texas Southwestern Medical School and following his residency in internal medicine there, he completed fellowship training in hematology-oncology at the UCLA School of Medicine.
Positions
- Company NameAlkermes plcStock CodeALKSPositionIndependent DirectorColleagues
- BCBlair C. JacksonPresident, CEO & Director
- RFRichard F. PopsChairman
- JRJoshua ReedSenior VP & CFO
- DJDavid Joseph GaffinExecutive VP, Chief Legal Officer, Chief Compliance Officer & Secretary
- CCCraig C. HopkinsonExecutive VP of Research & Development and Chief Medical Officer
- CTChristian Todd NicholsSenior VP & Chief Commercial Officer
- SMShane Martin CookeIndependent Director
- BPBrian P. McKeonIndependent Director
